Poxel S.A. (EPA:POXEL)
France flag France · Delayed Price · Currency is EUR
0.5600
0.00 (0.00%)
Jul 29, 2025, 5:35 PM CET

Poxel Company Description

Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases.

The company’s lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan.

It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH); PXL065, an earlier stage programs that is in Phase 2 for the treatment of NASH focusing on chronic and rare metabolic indications.

The company has a licensing agreement with Enyo Pharma S.A.S. for the development of farnesoid X receptor that is in Phase 2a study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial dysfunction; and Sumitomo Pharma for development and commercialization of Imeglimin.

Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.

Poxel S.A.
Poxel logo
CountryFrance
Founded2009
IndustryBiotechnology
SectorHealthcare
Employees6
CEOThomas Kuhn

Contact Details

Address:
Immeuble Le Sunway
Lyon, Auvergne 69007
France
Phone33 1 44 71 94 94
Websitepoxelpharma.com

Stock Details

Ticker SymbolPOXEL
ExchangeEuronext Paris
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyEUR
ISIN NumberFR0012432516
SIC Code2836

Key Executives

NamePosition
Thomas Kuhn M.B.A., Pharm D MBA, Pharm.D.Co-Founder, Chief Executive Officer, MD and Director
Fanny BosaVice President of Finance and Administration
Arthur RouilleInvestor Relations Officer
Sylvie BertrandSenior Vice President of Human Resources
Tejdeep BawaVice President and Head of Business Development